title: Next-generation sequencing of Chinese stage IV lung cancer patients reveals an association between EGFR mutation status and survival outcome.
abstract: Large-scale genomic characterization of non-small cell lung cancer (NSCLC) has revealed several putative oncogenic driver mutations that may constitute druggable therapeutic targets. However, there are little data to suggest that such gene alterations have clinical relevance. Over 12 consecutive months, tumor biopsy samples from 80 patients with stage IV NSCLC were analyzed for mutations in selected exons of 508 cancer-related genes using next-generation sequencing. From 85 specimens referred for genomic characterization, 80 (94%) specimens were successfully genotyped, and all had identifiable somatic alterations. Epidermal growth factor receptor (EGFR) and TP53 genes contained the highest frequency of observed mutations (65% and 40%, respectively) in the stage IV NSCLC cases. Notably, patients with EGFR mutations showed a significantly shorter survival time compared with patients expressing wild-type EGFR (p = 0.0053). Moreover, of the 32 patients harboring EGFR mutations, EGFR-L858R mutant patients showed a significantly shorter survival time compared with patients with other EGFR mutations (p = 0.036). In conclusion, tumors from stage IV NSCLC patients harbor characteristic gene alterations, of which EGFR L858R in particular appears to be a poor prognostic factor for overall survival.
authors.affiliation: Department of Gynecology, Tianjin First Center Hospital, Tianjin, China.|Department of Oncology Research, Tianjin HengJia Biotechnology Development Co, Ltd., Tianjin, China.
authors.forename: F
authors.initials: F
authors.lastname: Li
authors.affiliation: Department of Oncology, Tianjin Beichen Hospital, Tianjin, China.
authors.forename: X
authors.initials: X
authors.lastname: Du
authors.affiliation: Department of Integrated Chinese and Western Medicine Treatment Center, Henan Cancer Hospital, Zhengzhou, China.
authors.forename: H
authors.initials: H
authors.lastname: Zhang
authors.affiliation: Department of Oncology, Tianjin Beichen Hospital, Tianjin, China.
authors.forename: T
authors.initials: T
authors.lastname: Ju
authors.affiliation: Department of Oncology, Tianjin Beichen Hospital, Tianjin, China.
authors.forename: C
authors.initials: C
authors.lastname: Chen
authors.affiliation: Department of Gynecology, Tianjin First Center Hospital, Tianjin, China.
authors.forename: Q
authors.initials: Q
authors.lastname: Qu
authors.affiliation: Department of Lymphoma & Myeloma, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
authors.forename: X
authors.initials: X
authors.lastname: Zhang
authors.affiliation: Laboratory of Molecular Neuro-Oncology, Texas Children's Cancer Center, Houston, TX, USA.
authors.forename: L
authors.initials: L
authors.lastname: Qi
authors.affiliation: Department of Melanoma Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.|Department of Immunology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
authors.forename: G
authors.initials: G
authors.lastname: Lizée
mesh_terms: D000328:Adult; D000368:Aged; D044466:Asian People; D014408:Biomarkers, Tumor / Q000235:genetics*; D018572:Disease-Free Survival; D066246:ErbB Receptors / Q000235:genetics*; D005260:Female; D059014:High-Throughput Nucleotide Sequencing; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009367:Neoplasm Staging; D011379:Prognosis
chemical_list: D014408:Biomarkers, Tumor; C512478:EGFR protein, human; D066246:ErbB Receptors
keywords: epidermal growth factor receptor (EGFR); gene mutation; next-generation sequencing; non-small cell lung cancer (NSCLC); prognosis; survival